Combined tumor plus nontumor interim FDG-PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer

Sebastian Zschaeck, Yimin Li, Rebecca Bütof, Chen Lili, Wu Hua, Esther C G Troost, Marcus Beck, Holger Amthauer, David Kaul, Jörg Kotzerke, Alexander D J Baur, Pirus Ghadjar, Michael Baumann, Mechthild Krause, Frank Hofheinz, Sebastian Zschaeck, Yimin Li, Rebecca Bütof, Chen Lili, Wu Hua, Esther C G Troost, Marcus Beck, Holger Amthauer, David Kaul, Jörg Kotzerke, Alexander D J Baur, Pirus Ghadjar, Michael Baumann, Mechthild Krause, Frank Hofheinz

Abstract

We have investigated the prognostic value of two novel interim 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) parameters in patients undergoing chemoradiation (CRT) for esophageal squamous cell carcinoma (ESCC): one tumor parameter (maximal standardized uptake ratio rSUR) and one normal tissue parameter (change of FDG uptake within irradiated nontumor-affected esophagus ∆SUVNTO ). PET data of 134 European and Chinese patients were analyzed. Parameter establishment was based on 36 patients undergoing preoperative CRT plus surgery, validation was performed in 98 patients receiving definitive CRT. Patients received PET imaging prior and during fourth week of CRT. Clinical parameters, baseline PET parameters, and interim PET parameters (rSUR and ∆SUVNTO ) were analyzed and compared to event-free survival (EFS), overall survival (OS), loco-regional control (LRC) and freedom from distant metastases (FFDM). Combining rSUR and ∆SUVNTO revealed a strong prognostic impact on EFS, OS, LRC and FFDM in patients undergoing preoperative CRT. In the definitive CRT cohort, univariate analysis with respect to EFS revealed several staging plus both previously established interim PET parameters as significant prognostic factors. Multivariate analyses revealed only rSUR and ∆SUVNTO as independent prognostic factors (p = 0.003, p = 0.008). Combination of these parameters with the cutoff established in preoperative CRT revealed excellent discrimination of patients with a long or short EFS (73% vs. 17% at 2 years, respectively) and significantly discriminated all other endpoints (OS, p < 0.001; LRC, p < 0.001; FFDM, p = 0.02), even in subgroups. Combined use of interim FDG-PET derived parameters ∆SUVNTO and rSUR seems to have predictive potential, allowing to select responders for definitive CRT and omission of surgery.

Keywords: chemoradiation; esophageal cancer; interim PET; normal tissue FDG uptake; personalized treatment; standardized uptake ratio.

© 2020 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.

References

    1. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086-92.
    1. van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84.
    1. Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the Esophagus (NEOCRTEC5010): a phase III Multicenter, randomized, open-label clinical trial. J Clin Oncol 2018;36:2796-803.
    1. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-7.
    1. Bedenne L, Michel P, Bouché O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;25:1160-8.
    1. Naik KB, Liu Y, Goodman M, et al. Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: an analysis of the National Cancer Data Base. Cancer 2017;123:3476-85.
    1. Kranzfelder M, Schuster T, Geinitz H, et al. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg 2011;98:768-83.
    1. Baumann M, Krause M, Overgaard J, et al. Radiation oncology in the era of precision medicine. Nat Rev Cancer 2016;16:234-49.
    1. Cremonesi M, Garibaldi C, Timmerman R, et al. Interim 18F-FDG-PET/CT during chemo-radiotherapy in the management of oesophageal cancer patients. A systematic review. Radiother Oncol 2017;125:200-12.
    1. Ku GY, Kriplani A, Janjigian YY, et al. Change in chemotherapy during concurrent radiation followed by surgery after a suboptimal positron emission tomography response to induction chemotherapy improves outcomes for locally advanced esophageal adenocarcinoma. Cancer 2016;122:2083-90.
    1. Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994;35:1308-12.
    1. Huang SC. Anatomy of SUV Standardized uptake value. Nucl Med Biol 2000;27:643-6.
    1. Keyes JW. SUV: Standard uptake or silly useless value? J Nucl Med 1995;36:1836-9.
    1. van den Hoff J, Oehme L, Schramm G, et al. The PET-derived tumor-to-blood standard uptake ratio (SUR) is superior to tumor SUV as a surrogate parameter of the metabolic rate of FDG. EJNMMI Res 2013;3:77.
    1. van den Hoff J, Lougovski A, Schramm G, et al. Correction of scan time dependence of standard uptake values in oncological PET. EJNMMI Res 2014;4:18.
    1. Hofheinz F, van den Hoff J, Steffen IG, et al. Comparative evaluation of SUV, tumor-to-blood standard uptake ratio (SUR), and dual time point measurements for assessment of the metabolic uptake rate in FDG PET. EJNMMI Res 2016;6:53.
    1. Hofheinz F, Apostolova I, Oehme L, et al. Test-retest variability in lesion SUV and lesion SUR in 18F-FDG PET: an analysis of data from two prospective multicenter trials. J Nucl Med 2017;58:1770-5.
    1. Bütof R, Hofheinz F, Zöphel K, et al. Prognostic value of SUR in patients with trimodality treatment of locally advanced esophageal carcinoma. J Nucl Med 2018;60:192-8.
    1. Hofheinz F, Bütof R, Apostolova I, et al. An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET. EJNMMI Res 2016;6:19.
    1. Bütof R, Hofheinz F, Zöphel K, et al. Prognostic value of pretherapeutic tumor-to-blood standardized uptake ratio in patients with Esophageal carcinoma. J Nucl Med 2015;56:1150-6.
    1. Li Y, Hofheinz F, Furth C, et al. Increased evidence for the prognostic value of FDG uptake on late-treatment PET in non-tumour-affected oesophagus in irradiated patients with oesophageal carcinoma. Eur J Nucl Med Mol Imaging 2018;45:1752-61.
    1. Zschaeck S, Hofheinz F, Zöphel K, et al. Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy. Eur J Nucl Med Mol Imaging 2017;44:1813-22.
    1. Li Y, Lin Q, Luo Z, et al. Wu H. value of sequential 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in prediction of the overall survival of esophageal cancer patients treated with chemoradiotherapy. Int J Clin Exp Med 2015;8:10947-55.
    1. Hofheinz F, Pötzsch C, Oehme L, et al. Automatic volume delineation in oncological PET. Evaluation of a dedicated software tool and comparison with manual delineation in clinical data sets. Nuklearmedizin 2012;51:9-16.
    1. Hofheinz F, Langner J, Petr J, et al. An automatic method for accurate volume delineation of heterogeneous tumors in PET. Med Phys 2013;40:082503.
    1. Zhuang H, Pourdehnad M, Lambright ES, et al. Dual time point 18F-FDG PET imaging for differentiating malignant from inflammatory processes. J Nucl Med 2001;42:1412-7.
    1. Yang Z, Zan Y, Zheng X, et al. Dynamic FDG-PET imaging to differentiate malignancies from inflammation in subcutaneous and in situ mouse model for non-small cell lung carcinoma (NSCLC). PLoS One 2015;10:e0139089.
    1. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing, 2018.
    1. Li Y, Hofheinz F, Furth C, et al. Increased evidence for the prognostic value of FDG uptake on late-treatment PET in non-tumour-affected oesophagus in irradiated patients with oesophageal carcinoma. Eur J Nucl Med Mol Imaging 2018;45:1752-61.
    1. Mikhail S, Wei L, Salem ME, et al. Outcomes of definitive chemoradiation in patients with esophageal cancer. Dis Esophagus 2017;30:1-7.
    1. Shao MS, Wong AT, Schwartz D, et al. Definitive or preoperative chemoradiation therapy for esophageal cancer: patterns of care and survival outcomes. Ann Thorac Surg 2016;101:2148-54.
    1. Chen X, Wang L, Li P, et al. Dual TGF-β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8+ T cell response in esophageal squamous cell carcinoma. Int J Cancer 2018;143:2561-74.
    1. Tang TT, Rendon DA, Zawaski JA, et al. Imaging radiation-induced gastrointestinal, bone marrow injury and recovery kinetics using 18F-FDG PET. PLoS One 2017;12:e0169082.
    1. Mehmood Q, Sun A, Becker N, et al. Predicting radiation esophagitis using 18F-FDG PET during chemoradiotherapy for locally advanced non-small cell lung cancer. J Thorac Oncol 2016;11:213-21.
    1. Niedzielski JS, Yang J, Liao Z, et al. (18)F-Fluorodeoxyglucose positron emission tomography can quantify and predict esophageal injury during radiation therapy. Int J Radiat Oncol Biol Phys 2016;96:670-8.
    1. Buscombe J. PET imaging of inflammation. Q J Nucl Med Mol Imaging 2014;58:284-9.
    1. Ko JM-Y, Ning L, Zhao X-K, et al. BRCA2 loss-of-function germline mutations are associated with esophageal squamous cell carcinoma risk in Chinese. Int J Cancer 2019;146:1042-51.
    1. Hicks RJ, Mac Manus MP, Matthews JP, et al. Early FDG-PET imaging after radical radiotherapy for non-small-cell lung cancer: inflammatory changes in normal tissues correlate with tumor response and do not confound therapeutic response evaluation. Int J Radiat Oncol Biol Phys 2004;60:412-8.
    1. Zschaeck S, Löck S, Leger S, et al. FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy. Radiother Oncol 2017;122:437-44.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren